QT Imaging Holdings (QTI) Earnings Date & Reports

Key Takeaways

• QT Imaging Holdings (QTI) is scheduled to report its third quarter 2026 results on November 10, 2026, after the market close, with a conference call at 4:30 p.m. Eastern Time.
• Wall Street consensus projects revenue of roughly $10.79 million, more than doubling the $4.19 million reported in the year-ago quarter, alongside a net loss of about $0.09 per share.
• Investors will focus on scanner shipment volume and gross margin, which narrowed to 41% in the second quarter of 2026, down from 50% a year earlier.
• Recent catalysts, including Medicare outpatient reimbursement for QTscan effective January 2027 and a first Gulf Cooperation Council commercial order, set the stage for the quarter's narrative.
• The company reaffirmed full-year 2026 revenue guidance of approximately $39 million, a level that hinges on fulfilling distribution minimum order quantities.
• For more detail on QTI's Major News, Today's Price Move, Price Targets, and Forecast, explore Tickeron's dedicated pages.
• To discover AI-driven trading ideas across the broader market, explore Trending AI Robots.

Earnings Context and Why It Matters

QT Imaging Holdings, a medical device company commercializing its Breast Acoustic CT Scanner, is in the early stages of a rapid revenue ramp. Full-year 2025 revenue rose roughly 288% to $18.9 million, and management has guided to approximately $39 million for 2026. This quarter's report is a key test of whether that trajectory is sustainable as the company balances top-line growth against rising costs and narrowing gross margins. For investors, the results will clarify how effectively newly secured reimbursement, regulatory, and distribution milestones are translating into commercial momentum, and whether the company can narrow its losses while continuing to scale scanner placements.

Earnings Expectations

Analysts expect QT Imaging Holdings to report revenue of approximately $10.79 million for the third quarter of 2026, which would represent growth of more than 150% compared with $4.19 million in the same period a year earlier. Consensus estimates call for a net loss of roughly $0.09 per share, a notable improvement from the $0.47 per-share loss recorded in the third quarter of 2025.

The company enters the report having just affirmed full-year 2026 revenue guidance of approximately $39 million. Key metrics investors will monitor include the number of Breast Acoustic CT scanners shipped, gross margin (which declined to 41% in the second quarter of 2026 from 50% a year earlier), operating expenses, and cash burn. Recent quarters show a mixed track record against estimates: second quarter 2026 revenue of $7.44 million missed the $7.60 million consensus, while first quarter 2026 revenue of $6.53 million modestly exceeded the $6.45 million estimate. Historically, the stock has reacted sharply to results, falling roughly 16.7% after first quarter 2026 earnings and about 5.3% after the second quarter report.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful resource for investors monitoring earnings-driven moves like those around QTI's quarterly results.

Market Reaction and Investor Sentiment

Sentiment heading into the third quarter 2026 report remains cautious. QTI shares have declined significantly over the past year, trading near the lower end of their 52-week range, and prior earnings events have triggered sharp intraday moves. The market's focus is split between the company's impressive revenue growth and its persistent losses, with margin compression and higher operating expenses weighing on the investment thesis. Key risk factors include execution on large distribution minimum order quantities, the pace of scanner adoption, and geopolitical disruptions that have previously affected commercial activity in parts of the Gulf region. Any shortfall in revenue or an unexpected widening of losses could amplify volatility given the stock's thin trading volume.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors will be listening for management's progress on several fronts that could shape the next several quarters. First is the fulfillment of distribution minimum order quantities, which underpin the company's roughly $39 million revenue target for 2026 and represent a substantial contracted backlog through 2028.

Second, reimbursement and regulatory milestones remain pivotal. The Medicare outpatient reimbursement classification for QTscan, effective January 2027, and the newly effective CPT Category III code could support broader hospital adoption, while regulatory approvals in markets such as Saudi Arabia and the United Arab Emirates may unlock international distribution.

Finally, investors should watch cost trends and liquidity. Gross margin recovery, control of operating expenses, and cash burn will be closely scrutinized, as the company works to narrow losses and move toward a more sustainable financial profile. How management addresses the geopolitical factors affecting Gulf-region shipments will also be an important signal for the durability of near-term revenue growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations